Anonymous sources say that Baxter (NYSE:BAX) is pursuing an acquisition of Swedish medical device company Gambro for $4 billion, according to Reuters and the Wall Street Journal.
Deerfield, Ill.-based Baxter could ink the deal in the next 2 or 3 weeks, Reuters reported.
Gambro’s owners, a pair of Scandinavian private equity firms, declined to comment or weren’t available, the newswire reported.
Sign up to get our free newsletters delivered straight to your inbox
The move would bolster Baxter’s renal dialysis business, adding Gambro’s hemodialysis devices to its peritoneal dialysis offering.
U.S. tax policy pushes investments offshore
Medtronic (NYSE:MDT) had to borrow to fund its $816 million buyout of China Kanghui Holdings, because some 94% of its $10 billion cash reserve is tied up in offshore accounts – just 1 example of U.S. tax policy making it more attractive to invest overseas, according to Charlie Kelly
For companies like Covidien (NYSE:COV) that are based offshore, however, the tax code makes it much more appealing to buy in the U.S. Although Covidien runs most of its operations from Mansfield, Mass., it’s technically headquartered in Dublin, where it enjoys a 12.5% tax rate, as much as 25% lower than in the U.S. So Covidien could afford to spend $2.6 billion on Plymouth, Minn.-based ev3 in 2010, Kelly writes.
Read more
Thoratec OKs $150M buyback
Thoratec (NSDQ:THOR) authorized a share repurchasing program of up to $150 million, with JP Morgan agreeing to sell off $75 million worth of stock right off the bat.
Read more
Zimmer reassures SEC on Iran, Syria sales
Zimmer Holdings said its businesses in Iran and Syria are fully compliant with U.S. laws governing trade with those nations, which the U.S. labels as state sponsors of terrorism.
Read more
Mauna Kea inks development deal with University of Edinburgh
Mauna Kea (ENT:MKEA) inked a deal with The University of Edinburgh to develop a molecular imaging device for use with its Cellvizio confocal laser endomicroscope.
Read more
- Baxter (NYSE:BAX): Stifel Nicolaus initiates coverage with "hold" rating.
- Boston Scientific (NYSE:BSX): Citigroup raises from "neutral" to "buy" rating, increases price target from $5.30 to $7.30; Stifel Nicolaus initiates coverage with "buy" rating, $6.50 price target.
- C.R. Bard (NYSE:BCR): Brean Capital initiates coverage with “hold” rating.
- CareFusion (NYSE:CFN): Stifel Nicolaus initiates coverage with "buy" rating, $33 price target.
- Covidien (NYSE:COV): Stifel Nicolaus initiates coverage with "hold" rating.
- Edwards Lifesciences (NYSE:EW): Stifel Nicolaus initiates coverage with "buy" rating, $113 price target.
- HeartWare International (NSDQ:HTWR): UBS downgrades to "neutral" from "buy" rating, sets $95 price target; Leerink Swann maintains "outperform" rating, raises price target to $105 from $100; Wedbush Securities raises price target from $101 to $105, maintains "outperform" rating.
- Intuitive Surgical (NSDQ:ISRG): Stifel Nicolaus initiates coverage at “hold” rating
- Johnson & Johnson (NYSE:JNJ): Stifel Nicolaus initiates coverage with "hold" rating.
- Medtronic (NYSE:MDT): Citigroup reiterates "buy" rating, increases price target from $47 to $50; Credit Suisse Group reiterates "neutral" rating, raises price target from $46 to $47; Deutsche Bank raises price target from $43 to $45, maintains "hold" rating; Leerink Swann reiterates "market perform" rating, $43 price target; Mizuho raises price target from $41 to $43, maintains "neutral" rating; Northland Securities maintains "market perform" rating, raises price target from $44 to $46; Piper Jaffray raises price target from $45 to $48, reiterates "overweight" rating; Stifel Nicolaus initiates coverage with "hold" rating.
- Optos plc (LON:OPTS): Jefferies Group reiterates “buy” rating, $4.46 price target; Peel Hunt downgrades from "hold" to "sell" rating.
- Siemens (NYSE:SI): Deutsche Bank reduces from "hold" to "sell" rating.
- St. Jude Medical (NYSE:STJ): Citigroup reiterates "sell" rating, reduces price target from $32 to $30; Stifel Nicolaus initiates coverage with "hold" rating; Wells Fargo downgrades to "market perform" rating.
- Stryker (NYSE:SYK): Stifel Nicolaus initiates coverage with "buy" rating, $65 price target.
- Zimmer (NYSE:ZMH): Stifel Nicolaus initiates coverage with "hold" rating.